Anubha Mahajan

Anubha Mahajan is a human genetics researcher whose career has focused on genetic analysis of complex traits, with an emphasis on type 2 diabetes. Mahajan has co-led and led analysis of high-throughput genetic studies as part of large international consortia, such as DIAGRAM,^[1] GoT2D,^[2] T2D-GENES,^[3] and DIAMANTE,^[4] that explore the genetic architecture of type 2 diabetes. More recently, she has moved from genetic discovery to utilizing human genetics research to understand the pathophysiological mechanisms that contribute to type 2 diabetes.

Education[edit]

Mahajan completed her PhD at the Dr. B.R. Ambedkar Centre for Biomedical Research at the University of Delhi. Subsequently, she worked as Research Associate at the Institute of Genomics and Integrative Biology at the Council of Scientific and Industrial Research, New Delhi. Until January 2020, she was Senior Team Leader in Human Genetics in the McCarthy/Diabetes Group at the Wellcome Centre for Human Genetics at the University of Oxford. Currently, she is a Senior Scientist at Genentech.

Research career[edit]

Mahajan has been a prolific and leading researcher in the field of human genetics, specifically with regard to type 2 diabetes. In 2018, she lead-authored two manuscripts published in Nature Genetics. One study focused on refining the accuracy of validated target identification through fine-mapping of coding variants in type 2 diabetes.^[5] The other publication focused on using high-density imputation and pancreatic islet-specific epigenome maps to fine-map type 2 diabetes susceptibility loci to a single genetic variant-resolution.^[6]

References[edit]

^ Mahajan A, Go MJ, Zhang W, Below JE, Gaulton KJ, Ferreira T, et al. (DIAbetes Genetics Replication And Meta-analysis (DIAGRAM) Consortium; Asian Genetic Epidemiology Network Type 2 Diabetes (AGEN-T2D) Consortium; South Asian Type 2 Diabetes (SAT2D) Consortium; Mexican American Type 2 Diabetes (MAT2D) Consortium; Type 2 Diabetes Genetic Exploration by Nex-generation sequencing in muylti-Ethnic Samples (T2D-GENES) Consortium) (March 2014). "Genome-wide trans-ancestry meta-analysis provides insight into the genetic architecture of type 2 diabetes susceptibility". Nature Genetics. 46 (3): 234–44. doi:10.1038/ng.2897. PMC 3969612. PMID 24509480.
^ "dbGaP | phs000840.v1.p1 | The Genetics of Type 2 Diabetes Consortium (GoT2D): Low-Pass Sequencing and High-Density SNP Genotyping for Type 2 Diabetes". www.ncbi.nlm.nih.gov. Retrieved 24 May 2019.
^ Mahajan A, Go MJ, Zhang W, Below JE, Gaulton KJ, Ferreira T, et al. (Charge Diabetes Working Group; EPIC-InterAct Consortium; EPIC-CVD Consortium; GOLD Consortium; VA Million Veteran Program) (December 2017). "Exome-wide association study of plasma lipids in >300,000 individuals". Nature Genetics. 49 (12): 1758–1766. doi:10.1038/ng.3977. PMC 5709146. PMID 29083408.
^ Costanzo M (8 October 2018). "Type 2 Diabetes Knowledge Portal News: DIAMANTE GWAS dataset adds close to a million samples along with fine-mapping to the T2DKP". Type 2 Diabetes Knowledge Portal News. Retrieved 24 May 2019.
^ Mahajan A, Wessel J, Willems SM, Zhao W, Robertson NR, Chu AY, et al. (ExomeBP Consortium; MAGIC Consortium; GIANT Consortium) (April 2018). "Refining the accuracy of validated target identification through coding variant fine-mapping in type 2 diabetes". Nature Genetics. 50 (4): 559–571. doi:10.1038/s41588-018-0084-1. PMC 5898373. PMID 29632382.
^ Mahajan A, Taliun D, Thurner M, Robertson NR, Torres JM, Rayner NW, et al. (DIAMANTE consortium) (November 2018). "Fine-mapping type 2 diabetes loci to single-variant resolution using high-density imputation and islet-specific epigenome maps". Nature Genetics. 50 (11): 1505–1513. doi:10.1038/s41588-018-0241-6. PMC 6287706. PMID 30297969.

External links[edit]

Anubha Mahajan publications indexed by Google Scholar
Anubha Mahajan's webpage at Wellcome Centre for Human Genetics

[1] Mahajan A, Go MJ, Zhang W, Below JE, Gaulton KJ, Ferreira T, et al. (DIAbetes Genetics Replication And Meta-analysis (DIAGRAM) Consortium; Asian Genetic Epidemiology Network Type 2 Diabetes (AGEN-T2D) Consortium; South Asian Type 2 Diabetes (SAT2D) Consortium; Mexican American Type 2 Diabetes (MAT2D) Consortium; Type 2 Diabetes Genetic Exploration by Nex-generation sequencing in muylti-Ethnic Samples (T2D-GENES) Consortium) (March 2014). "Genome-wide trans-ancestry meta-analysis provides insight into the genetic architecture of type 2 diabetes susceptibility". Nature Genetics. 46 (3): 234–44. doi:10.1038/ng.2897. PMC 3969612. PMID 24509480.

[2] "dbGaP | phs000840.v1.p1 | The Genetics of Type 2 Diabetes Consortium (GoT2D): Low-Pass Sequencing and High-Density SNP Genotyping for Type 2 Diabetes". www.ncbi.nlm.nih.gov. Retrieved 24 May 2019.

[3] Mahajan A, Go MJ, Zhang W, Below JE, Gaulton KJ, Ferreira T, et al. (Charge Diabetes Working Group; EPIC-InterAct Consortium; EPIC-CVD Consortium; GOLD Consortium; VA Million Veteran Program) (December 2017). "Exome-wide association study of plasma lipids in >300,000 individuals". Nature Genetics. 49 (12): 1758–1766. doi:10.1038/ng.3977. PMC 5709146. PMID 29083408.

[4] Costanzo M (8 October 2018). "Type 2 Diabetes Knowledge Portal News: DIAMANTE GWAS dataset adds close to a million samples along with fine-mapping to the T2DKP". Type 2 Diabetes Knowledge Portal News. Retrieved 24 May 2019.

[5] Mahajan A, Wessel J, Willems SM, Zhao W, Robertson NR, Chu AY, et al. (ExomeBP Consortium; MAGIC Consortium; GIANT Consortium) (April 2018). "Refining the accuracy of validated target identification through coding variant fine-mapping in type 2 diabetes". Nature Genetics. 50 (4): 559–571. doi:10.1038/s41588-018-0084-1. PMC 5898373. PMID 29632382.

[6] Mahajan A, Taliun D, Thurner M, Robertson NR, Torres JM, Rayner NW, et al. (DIAMANTE consortium) (November 2018). "Fine-mapping type 2 diabetes loci to single-variant resolution using high-density imputation and islet-specific epigenome maps". Nature Genetics. 50 (11): 1505–1513. doi:10.1038/s41588-018-0241-6. PMC 6287706. PMID 30297969.

[1]

[2]

[3]

[4]

[5]

[6]